Skip to content

Self-monitoring and personalized feedback as a tool to boost depression treatment

Self-monitoring and personalized feedback as a tool to boost depression treatment - ZELF-i

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON42825
Enrollment
150
Registered
2016-01-18
Start date
2016-05-16
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression depressive disorder

Interventions

28 days of systematic self-monitoring (5 times per day) with weekly personalized feedback. The Do-module focuses on positive affect and activities, the Think-module focuses on negative affect and th

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Depression treatment is indicated by the practitioner - Aged between 18 and 65 years - Written informed consent

Exclusion criteria

Exclusion criteria: - Crisis intervention warranted (i.e. in the case of acute suicidality) - Presence of psychotic or manic symptoms - Inadequate Dutch language proficiency, significant auditory or visual impairments or mental retardation

Design outcomes

Primary

MeasureTime frame
The primary outcome measure to determine effectiveness of the intervention will be change in depression symptom severity as measured by the self-report Inventory of Depressive Symptomatology (IDS-SR, Rush et al., 1999) across 6 time points: pre-ESM, after 4 weeks of ESM and at 4 follow-ups at 4, 8, 12, and 24 weeks (post-ESM).

Secondary

MeasureTime frame
From a patient perspective, functional outcomes are at least as relevant as clinical outcomes. Therefore, we will also assess change in psychosocial functioning by means of the Outcome Questionnaire (OQ-45, Lambert et al., 1996). Moreover, we will assess the extent to which individuals regain self-esteem and take control over their own lives by means of the Dutch Empowerment questionnaire (NEL; Boevink, Kroon, & Giesen, 2010). This questionnaire has been developed by the Trimbos institute in collaboration with individuals with psychiatric problems. Other outcome measures: Questionnaires regarding cost-effectiveness: PRODISQ, TiC-P, en Euroqol-5D Baseline characteristics: demographics, LEIDS-R (Cognitive Reactivity), TAS-20 (Alexithymia)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)